South Africa proposes limiting drug patent extensions

04/23/2013 | PharmaLive.com

South Africa has announced plans to limit the ability of drug firms to win patent extensions for brand-name drugs by changing or modifying them in minor ways. Critics allege that such extensions block patients from receiving cheaper and more affordable versions of life-saving medications for such conditions as HIV/AIDS. The South African move comes barely a month after India rejected a patent extension request from Novartis for its best-selling Gleevec cancer treatment.

View Full Article in:

PharmaLive.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ